An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Observational · No treatment assigned · 1 site · Shanghai East Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflammatory Bowel Disease (IBD) and Metabolic Dysfunction Associated Fatty Liver Disease. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Subjects aged over 18 years (including borderline values), of either sex.
- Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD;
- Subjects able to cooperate with follow-up, participate in this study and sign the informed consent.
There are also 4 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 337 participants are expected to take part.
- Start date: 2025-05-01 (planned).
- Main results expected around 2027-12-01 (estimate from the record).
- 1 study site listed (1 marked recruiting) in China.
Main thing being measured
- Clinical remission or Endoscopic remission (Follow-up for 54 weeks)
In the researchers’ words
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has increased dramatically in China, and it will become a common disease of digestive system in China.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflammatory Bowel Disease (IBD); Metabolic Dysfunction Associated Fatty Liver Disease |
| Lead sponsor | Shanghai East Hospital |
| Collaborators | Shanghai Pudong New Area Health Commission; Dongfang Hospital Affiliated to Tongji University |
| Enrollment | 337 (estimated) |
| Start date | 2025-05-01 |
| Primary completion (est.) | 2027-12-01 |
| First posted | 2025-04-23 |
| Last updated | 2025-04-23 |
| Official title | A Bidirectional, Multicenter Cohort Study of Inflammatory Bowel Disease (IBD) Patients With Nonalcoholic Fatty Liver Disease (NAFLD) |
| ClinicalTrials.gov ID | NCT06939569 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: 1. Subjects aged over 18 years (including borderline values), of either sex. 2. Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD; 3. Subjects able to cooperate with follow-up, participate in this study and sign the informed consent. Exclusion Criteria: 1. Subjects with incomplete clinical data; 2. Subjects can not to cooperate with follow-up, and refuse to sign the informed consent; 3. Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women; 5.Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai East Hospital | Shanghai | China | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.